Validation of Psoriasis Diagnoses Recorded in Finnish Biobanks

Suvia HAVERINEN1, Armi VIHERVAA2, Ellisa LÖYTTYNYIEMI1, Sirkku PELTONEN2, Leena KOULU2, Kaisa TASANEN1* and Laura HUILAJÄ1 for the FinnGen investigators

1Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital; PEDEGO Research Unit, University of Oulu, FIN-90220 Oulu, 2Department of Dermatology, Turku University Hospital and University of Turku and 3Department of Biostatistics, University of Turku, Turku, Finland. *E-mail: kaisa.tasanen@oulu.fi

Accepted Oct 2, 2020; Epub ahead of print Oct 7, 2020

In clinical research, the use of data retrieved from health registries and biobank samples is becoming more common (1). The information contained in these data repositories is based on diagnoses entered into medical records during daily clinical practice. In general, Finnish health registries have been shown to be an accurate and reliable source of information (2), but the dermatological diagnoses contained therein have not previously been validated. This study aimed to validate the diagnostic code used to record cases of psoriasis in the databases of 2 Finnish biobanks (Oulu and Turku).

MATERIALS AND METHODS

In November–December 2019, biobank personnel retrieved the recent records of 100 consecutive patients containing the diagnostic code for psoriasis (International Classification of Diseases – 10th revision (ICD-10) code L40.0) from the Borealis biobank in Oulu, and 100 from the Auria biobank in Turku (www.finbb.fi). These biobanks are based on specialized (tertiary) care. Patients treated in the University hospitals of Oulu and Turku are asked for permission to include their biological samples in the biobank. Currently, there is no data about the participation rate. The records of 196 patients, matched by sex and age, containing the diagnostic code for type II diabetes mellitus (E11) were selected as a control group. The intention of the control group was to identify any unregistered diagnoses of psoriasis. Patients with diabetes were chosen because patients with psoriasis have an elevated risk of diabetes (3), and therefore selecting such a control group may have increased the likelihood of encountering unregistered cases of psoriasis. This study was approved by FinBB, which is a consortium of Finnish biobanks, and the University Hospitals of Oulu and Turku. Study data were collected and managed using REDCap electronic data capture tools (4) hosted at the University of Turku. Counts and percentages are presented for categorical variables. An exact 95% confidence interval (CI) was calculated for the positive predictive value (PPV).

Data were extracted from the patients’ electronic medical records by a dermatologist or experienced resident. The records of the psoriasis group were checked for clinical findings that are characteristic of psoriasis (sharply demarcated and erythematous papulosquamous lesions), but not of any other dermatological condition. Age at onset, psoriasis type, and receipt of any treatment used for psoriasis were recorded, as were any symptoms or diagnosis of psoriatic joint disease. A diagnosis was defined as “uncertain” if the record contained evidence clearly supporting a diagnosis, but the diagnosis was not set by dermatologist. The medical records of the control group were reviewed carefully in order to find cases of psoriasis that were not registered with the appropriate diagnostic code. The criterion for validity of a psoriasis diagnosis was that: (i) a dermatologist or a registrar had stated typical clinical findings for psoriasis; or (ii) psoriasis-like findings and one of the following: histological findings supporting a diagnosis, a recorded score on the Psoriasis Area Severity Index (PASI), nail findings typical of psoriasis, psoriatic arthritis diagnosed by a rheumatologist, or a note in the records of a first-degree relative with diagnosed psoriasis. Plaque psoriasis, psoriasis arthritis with typical skin symptoms and guttate psoriasis were accepted as “psoriasis” in this validation study.

RESULTS

Based on these criteria, the diagnosis in 12 patients from the psoriasis group could not be verified by the electronic medical records, and the diagnosis was uncertain for a further 12 patients. Consequently, the study found the PPV to be 88.0% (95% CI 82.7–92.2). All the patients with an “uncertain” diagnosis seemed to be psoriasis cases, but with symptoms so mild that they did not warrant a dermatological appointment at a university hospital and therefore lacked a confirmatory diagnosis by a dermatologist. Of those with a diagnosis recorded with the code L40.0, 12 records contained clinical findings typical of dermatological conditions other than psoriasis. Among these, findings consistent with pustulosis palmoplantaris were the most frequent, being present in 6 of the records. Three patients in the control group had psoriasis based on chart review, resulting in a negative predictive value (NPV) of 1.5%.

A small majority of the psoriasis group (51.0%) were males. Most cases had psoriasis vulgaris (Table I). A diagnosis of psoriasis arthropathica had been set for a quarter of cases, but almost half of patients had joint symptoms. This probably reflects the high frequency of arthrosis symptoms. We analysed the psoriasis treatments used by the 176 patients with a verified psoriasis diagnosis. More than half (57.3%) had received ultraviolet (UV) phototherapy and nearly as many (54.0%) systemic therapy other than biologics, of which methotrexate and acitretin were the most used. Biologics were used by 13.6%, with most of these having received only one biologic (Table I). There were no reports of psoriasis having been triggered by the use of biologic treatments.

DISCUSSION

A recent Italian study reported as high as 98.9% PPV for psoriasis when using either a dermatologist’s diagnosis or psoriasis medications as search criteria (5). A recent Danish study found a PPV of 97.1% among patients treated in tertiary referral dermatology clinics (6). The lower PPV (88.0%) found in the current study may be due to the fact that it was based on diagnosis codes registered in biobank registries rather than dermatology clinics. Our findings are

This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta

Acta Derm Venereol 2020; 100: adv00297
doi: 10.2340/00015555-3656

Society for Publication of Acta Dermato-Venereologica

Acta Derm Venereol 2020; 100: adv00297

Society for Publication of Acta Dermato-Venereologica

Acta Derm Venereol 2020; 100: adv00297
This study categorized as “uncertain” all psoriasis diagnoses that lacked verification by a dermatologist, although the chart review revealed these diagnoses to be reliable, but mild. This was the cases also for those 3 in control group who had psoriasis mentioned in their charts. This finding may disturb registry and biobank data-based research if the study and control populations are not large enough. It was decided not to collect the information about PASI scores because the procedure of administering the PASI differs between hospitals. However, since more than half of the current patients with psoriasis had been treated with UV-phototherapy and/or systemic treatments, their psoriasis can be defined as moderate-to-severe.

Based on these findings, we conclude that the use of the ICD-10 code L40.0 is a reasonably valid approach when selecting patients with psoriasis from biobank registries.

ACKNOWLEDGEMENTS

The FinnGen-project provided salaries for SH and AV. Conflicts of interest: SH has received an educational grant from Celgene. AV has received educational grants from AbbVie, Jansen, Novartis, and Celgene. LK has attended advisory boards for Abbvie, Eli Lilly, Janssen, Leo Pharma, Novartis, Sanofi, UCB Pharma. KT has received educational grants from Novartis and Pfizer and honoraria from Novartis, Abbvie, Janssen-Cilag, SanofiGenzyme and Lilly for consulting and/or speaking. LH has received educational grants from Shire, Janssen-Cilag, Novartis, AbbVie and LeoPharma, honoraria from SanofiGenzyme, Novartis, Abbvie and UCB Pharma for consulting and/or speaking and is an investigator for Abbvie. EL and SP have no conflicts of interest to declare.

REFERENCES

1. Mulder DS, Spicer J. Registry-based medical research: data dredging or value building to quality of care? Ann Thorac Surg 2019; 108: 274–282.
2. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 2012; 40: 505–515.
3. Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, Gonzalez-Parra E, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 2058–2073.
4. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neil L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
5. Pazzolo E, Ciampichini R, Cazzaniga S, Sampietro G, Zucchi A, Naldi L. Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy. Arch Dermatol Res 2020 Jul 5. [Epub ahead of print].
6. Loft ND, Andersen CH, Halling-Overgaard AS, Thyssen JP, Skov l, Egberg A. Validation of psoriasis diagnoses in the Danish National Patient Register. Acta Derm Venereol 2019; 99: 1037–1038.
7. Agari MM, Wu JH, Geifman JM, Salmon C, Curtis JR, Harroll LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoeconomics Drug Saf 2013; 22: 842–849.
8. Lofvendahl S, Theander E, Svensson A, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden – a population-based register study. PLoS One 2014; 9: e98024.
9. Icen M, Crowson CS, McEvoy MT, Gabriel SE, Maradit Kremers H. Potential misclassification of patients with psoriasis in electronic databases. J Am Acad Dermatol 2008; 59: 981–985.
10. Seminara NM, Abubakar K, Shin DB, Langan SM, Kimmel SE, Mar golis D, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011; 164: 602–609.
11. Dowlatsahi EA, Kavousi M, Nijsken T, Ikramat NA, Hofman A, Franco OH, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol 2013; 133: 2347–2354.

Table I. Demographics and treatment usage of the psoriasis group (n = 200)

| Characteristics                                | n (%)   |
|------------------------------------------------|---------|
| Male                                           | 102 (51.0) |
| Psoriasis diagnosis L40, n                      | 176     |
| Confirmed                                      | 12      |
| Incorrect                                      | 12      |
| Uncertain                                      | 12      |
| Symptoms in joints[1, n (%)                    | 94 (53.4) |
| Vulgaris                                       | 118 (67.0) |
| Guttate                                        | 7 (4.0)  |
| Psoriasis arthropatica with skin symptoms       | 51 (29.0) |
| Age at symptom onset, n (%)                    | 39 (22.8) |
| ≤19 years                                      | 24 (13.6) |
| 20–39 years                                    | 54 (30.7) |
| 40–59 years                                    | 49 (27.8) |
| 60–69 years                                    | 17 (9.7)  |
| Unknown                                        | 32 (18.2) |
| Treatments used at any time, n (%)             | 98 (57.3) |
| Any systemic treatment                         | 95 (53.9) |
| Number of systemic treatments (other than biologics)[2, n (%) | 81 (46.0) |
| 0                                              | 54 (30.7) |
| 1                                              | 33 (18.8) |
| ≥2                                             | 8 (4.5)   |
| Treatment regimens used at any time[2, n (%)    | 69 (72.6) |
| Methotrexate                                    | 61 (64.2) |
| Acitretin                                       | 10 (10.5) |
| Cyclosporine                                    | 2 (2.1)   |
| Fumarate                                        | 33 (18.8) |
| Apremilast                                      | 5 (5.3)   |
| Number of biologics used at any time[2, n (%)  | 152 (86.3) |
| 0                                              | 13 (7.4)  |
| 1                                              | 6 (3.4)   |
| ≥2                                             | 5 (2.8)   |

[1] Diagnosis was defined as “uncertain” if the diagnosis for psoriasis was found in the medical records but was not set by a dermatologist. [2] Proportion was calculated from the 176 patients with a confirmed psoriasis diagnosis. [n=171; data on UV phototherapy was unavailable for 4 of the patients with a verified diagnosis.}

[2] Proportion calculated from the 95 patients having had systemic treatment.

www.medicaljournals.se/acta